Does Ozempic Help With Addictions? Here's What the Studies Tell Us

Does Ozempic Help With Addictions? Here's What the Studies Tell Us

It all started with a lizard.

The first GLP-1 drug, exenatide, was derived from the saliva of the Gila monster, a venomous lizard of the American Southwest. Approved in 2005 for type 2 diabetes, it needed two injections a day, so it never took off. Its descendants did. Semaglutide, sold as Ozempic, arrived in 2017 as a once-weekly shot, and millions of people now take drugs in this family.

Then something odd happened. Patients started saying the drugs changed more than their appetite. Some said they stopped wanting a drink. Others said gambling, nicotine, even online shopping lost its pull.

Is that real, or is it a wishful rumor with a good origin story? Here is what the research says.

First, Why do people think Ozempic can curb addiction?

The idea began with patient reports. Boston University pharmacologists note that people taking GLP-1 drugs like Ozempic and Wegovy have described less interest in alcohol and nicotine, and possibly in compulsive behaviors such as gambling, nail-biting and online shopping. The same experts stress that, for these behaviors, current evidence is anecdotal and randomized trials are only now underway.

A National Institute on Drug Abuse (NIDA) blog post says the same: GLP-1 drugs have been reported anecdotally, including on social media platforms like Reddit, to help people curb problem behaviors, and it flags this as an area needing research.

How did scientists end up studying this?

In reverse, as one researcher puts it. Brown University addiction scientist Carolina Haass-Koffler explains that science usually moves from animal studies to human trials, but here dramatic effects showed up in people first. Labs are now working backward to explain them with animal and cellular models.

Boston University pharmacologists describe the same pattern: people on GLP-1 drugs report less interest in alcohol and nicotine, and possibly in compulsive behaviors like gambling, nail-biting and online shopping. Their caution is just as clear. For most of these behaviors, the current evidence is anecdotal, and randomized trials are only now getting underway.

It isn't the only surprising GLP-1 claim to go viral. Soval's fact check on whether GLP-1 drugs boost male fertility rated that claim Contested: the drugs appear unlikely to harm fertility, but credible experts disagree on whether any gains are direct or simply a byproduct of weight loss.

What might the drug be doing in the brain?

GLP-1 drugs mimic a hormone that helps regulate appetite and insulin. Researchers think they also reach the brain's reward system. According to Brown's addiction researcher, the drugs bind receptors in regions like the ventral tegmental area and nucleus accumbens, blunting dopamine release and reward signaling. In plain terms, the things that normally feel rewarding may feel a little less compelling.

That matters for addiction because the circuitry overlaps. A National Institute on Drug Abuse (NIDA) blog post notes that gambling disorder shares neurobiological features with substance use disorders, including dysregulated dopamine pathways. It is also the only behavioral addiction recognized in the DSM-5.

Keep one distinction in mind. For gambling, this is a hypothesis, not a demonstrated effect. A 2026 review calls GLP-1 drugs an exploratory therapeutic hypothesis that needs dedicated testing.

What do the studies actually show?

1. A small randomized trial in alcohol use disorder (JAMA Psychiatry, 2025)
This phase 2 trial compared weekly semaglutide with placebo in 48 adults with alcohol use disorder over nine weeks. Semaglutide reduced alcohol consumed in a lab test and weekly craving, though overall drinking days were not significantly changed.
The catch: it was small and short, and participants were not seeking treatment.

2. A longer trial in people seeking treatment (The Lancet, 2026)
This 26-week randomized trial enrolled treatment-seeking patients with both alcohol use disorder and obesity. Semaglutide at 2.4 mg weekly reduced alcohol consumption.
The catch: it covered alcohol only, in people with obesity.

3. A very large health-record study (BMJ, 2026)
This cohort study followed 606,434 US veterans with type 2 diabetes. Those who started a GLP-1 drug had lower risk of several substance use disorders, with reductions of 14% to 25%, than those who started an SGLT-2 inhibitor.
The catch: it was observational, and gambling was not one of the outcomes.

4. A mixed result for nicotine (2026)
In a phase 2a trial of daily smokers, as reported by Medscape, semaglutide did not significantly cut cigarettes per day but did lower nicotine craving.
The catch: we only have the secondhand report.

5. Gambling: no direct data yet
We found no randomized trial or observational study of GLP-1 drugs in gambling disorder. What exists are anecdotal reports.

Alcohol is where the case is strongest. Animal work backs it up: Brown's researcher notes that in rodent models, GLP-1 drugs reduced voluntary drinking, relapse and stress-induced alcohol seeking.

Registered trials are now testing semaglutide in opioid use disorder and in alcohol use disorder with fatty liver disease.

Why can't we just say "yes"?

Three gaps stand in the way.

1. Observational data can't prove cause. A University of Cambridge epidemiologist, quoted by the Science Media Centre, cautioned that unmeasured factors may still shape the BMJ results, and that randomized trials are needed before these drugs count as addiction treatments.

2. Basic questions are open. A Boston University pharmacologist says it's unclear whether the effect depends on obesity. Dose, treatment length and what happens after stopping are also unknown.

3. One addiction doesn't stand in for another. Alcohol results don't automatically carry over to gambling.

What about gambling, the claim going viral?

This is the question people search most, so Soval checked it directly on October 2, 2026. The rating: Insufficient evidence.

The reasons are straightforward. NIDA flags GLP-1 drugs for gambling as reported anecdotally on social media platforms like Reddit and as an area needing research. A July 2026 review in Clinics and Practice goes further, stating that no clinical evidence currently supports GLP-1 use in gambling disorder. Its authors call for a dedicated randomized trial before any clinical use.

The question keeps coming up partly because betting is easier to reach than ever. NIDA noted in late 2025 that sports betting was legal in 38 US states and the District of Columbia. Soval's fact check on New York's lawsuit against Kalshi covers one of the legal fights over where prediction markets end and gambling begins.

What actually treats gambling disorder today?

• CBT is first-line. NIDA says randomized trials consistently show CBT reduces gambling frequency, symptom severity and financial loss. England's NICE guideline recommends group CBT, or individual CBT when group isn't suitable.

• Naltrexone is the leading medication option. NIDA reports no drug is FDA-approved for gambling disorder, and opioid antagonists like naltrexone have the strongest evidence. A systematic review of 18 placebo-controlled trials points the same way. NICE suggests considering it when therapy hasn't worked or relapses repeat, noting this was off-label use as of January 2025.

• Support helps. NICE also recommends peer support and practical tools like gambling-blocking software.

The bigger problem is access. NIDA estimates only 7% to 12% of people with gambling disorder seek treatment or support groups.

Need help with gambling? In the US, call or text 1-800-GAMBLER. In the UK, see the NHS gambling support page. If someone is in immediate danger, contact emergency services.

What are the downsides?

• Side effects. Brown's researcher lists nausea, GI issues and sometimes a general loss of interest in things.

• Rebound. Whether people can stop without losing the benefit is described as a hot open question. The 2026 review notes weight typically returns after discontinuation.

• Off-label use isn't supported. The same review says prescribing for gambling disorder without another approved indication isn't supported by current evidence and belongs in a formal trial.

The bottom line

The Gila monster story is a good one, and the science behind it is real: GLP-1 drugs act on the brain's reward circuitry, and early randomized trials show promise for alcohol. But "help" is still a long way from "cure," and for gambling there is no direct clinical evidence yet. Until trials report, CBT remains the best-supported treatment, with naltrexone as a specialist-supervised option. We'll re-check as new studies land.

This article is informational and not medical advice. Talk to a qualified clinician before starting or stopping any medication.